We're glad you found us! If you're looking into GLP-1 medications such as Ozempic, Wegovy, Mounjaro, Zepbound, compounded semaglutide or compounded tirzepatide, you've probably noticed it's a bit chaotic out there. That's where we come in.
GLP Winner
We know it is difficult to compare pricing and providers directly. I was paying $875 a month for compounded tirzepatide. It's even more difficult to see where your compounded medications are coming from. Social media bombards us with ads and authentic, transparent prices are difficult to find. We want to make it easy to understand what a reasonable price is and what the safe options are for this often life-changing medication.
Clinical studies have demonstrated that, when prescribed appropriately, GLP-1 medications can significantly reduce all-cause mortality in patients with specific medical conditions.* It saves lives. We believe that safe, affordable access to these medications is a moral issue.
Our Long Term Vision
- Comparison resource for real people: We don't sell this - we help people compare options.
- We only show safe options: We believe safe compounding is in the public interest.
- Transparent pricing for telehealth providers.
- Transparent sourcing and potency testing for compounding pharmacies.
- Every medication prescribed by a licensed clinician.
About Us
I have personally struggled with obesity and navigating the medical system. This project started when we were spending hours researching GLP-1 providers ourselves. We built a spreadsheet to compare and then found additional spreadsheets on Reddit, but couldn't be sure if the info was current. When you added in the complexity of state by state and dosing options we knew we needed to build something.
We created GLP Winner to assist with price and sourcing transparency, finding real reviews, and navigating the healthcare space. We aim to keep addressing the needs of this community and others to come.
References
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
- Cardiovascular Protective Properties of GLP-1 Receptor Agonists: More than Just Diabetic and Weight Loss Drugs
- Cardiovascular and mortality outcomes with GLP-1 receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study